RT Journal Article
T1 Functional proteomics outlines the complexity of breast cancer molecular subtypes
A1 Gamez Pozo, A.
A1 Trilla Fuentes, L.
A1 Berges Soria, J.
A1 Selevsek, N.
A1 López Vacas, R.
A1 Díaz Almiron, M.
A1 Nanni, , P.
A1 Arevalillo, J. M.
A1 Navarro, H.
A1 Grossmann, J.
A1 Moreno, F. G.
A1 Rioja, R. G.
A1 Prado Vazquez, G.
A1 Zapater Moros, A.
A1 Main Yaque, Paloma
A1 Feliu, J.
A1 Del Prado, P.
A1 Zamora, P.
A1 Ciruelos Gil, Eva María
A1 Espinosa, E.
A1 Vara, J. A.F.
AB Breast cancer is a heterogeneous disease comprising a variety of entities with various genetic backgrounds. Estrogen receptor-positive, human epidermal growth factor receptor 2-negative tumors typically have a favorable outcome; however, some patients eventually relapse, which suggests some heterogeneity within this category. In the present study, we used proteomics and miRNA profiling techniques to characterize a set of 102 either estrogen receptor-positive (ER+)/progesterone receptorpositive (PR+) or triple-negative formalin-fixed, paraffin-embedded breast tumors. Protein expressionbased probabilistic graphical models and flux balance analyses revealed that some ER+/PR+ samples had a protein expression profile similar to that of triple-negative samples and had a clinical outcome similar to those with triple-negative disease. This probabilistic graphical model-based classification had prognostic value in patients with luminal A breast cancer. This prognostic information was independent of that provided by standard genomic tests for breast cancer, such as MammaPrint, OncoType Dx and the 8-gene Score.
PB Nature publishing group
SN 2045-2322
YR 2017
FD 2017
LK https://hdl.handle.net/20.500.14352/18103
UL https://hdl.handle.net/20.500.14352/18103
LA eng
NO Gámez-Pozo A, Trilla-Fuertes L, Berges-Soria J, Selevsek N, López-Vacas R, Díaz-Almirón M, et al. Functional proteomics outlines the complexity of breast cancer molecular subtypes. Sci Rep 2017;7:10100. https://doi.org/10.1038/s41598-017-10493-w.
NO Unión Europea. FP7
NO Instituto de Salud Carlos III
NO Ministerio de Economía, Comercio y Empresa (España)
DS Docta Complutense
RD 14 may 2025